P. L. Coutre

Phase 1 study of INNO‐406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome‐positive leukemias after imatinib resistance or intolerance

Arnon Nagler, Jorge Cortes, Andreas Hochhaus, 2010, Cancer.

Long-term treatment-free remission (TFR) following frontline (1L) nilotinib in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): ENESTfreedom 144-wk results.

J. Radich, S. Acharyya, F. Giles, 2018 .

A phase II study of nilotinib administered to patients with imatinib resistant or intolerant chronic myelogenous leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast crisis (BC) who also failed dasatinib

K. Bhalla, H. Kantarjian, F. Giles, 2007 .

Moxetumomab pasudotox in heavily pretreated patients with relapsed/refractory hairy cell leukemia: Results of a pivotal international study.

W. Wilson, I. Pastan, J. Delgado, 2018 .